Biotech Values

[DewDiligence]

BYSI IPOs 200K* shares @$20.00—with concurrent private placement of 2.54M shares at same price:

http://finance.yahoo.com/news/beyondspring-inc-prices-initial-public-120000456.html

BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington.

BeyondSpring is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia.

By offering only 200k shares to the general public, BYSI evidently wants to keep a tight rein on its shares. One would expect this to make BYSI a volatile trading stock.

*Assuming exercise of underwriter’s option.